Evommune Inc. (EVMN) vs Prelude Therapeutics Incorporated (PRLD)

Evommune Inc. and Prelude Therapeutics Incorporated are both Biotechnology companies. Evommune Inc. and Prelude Therapeutics Incorporated are of similar size ($318.4M and $309.9M). Evommune Inc. has the higher net margin (0.00% vs −269.8%) and the lower return on invested capital (−82.5% vs 0.00%). Across the 13 metrics below, Prelude Therapeutics Incorporated leads on 7 and Evommune Inc. on 6.

Valuation

Metric EVMN PRLD Biotechnology median
P/E n/m n/m 7.88
P/S n/m 17.02 11.47
P/B 1.10 2.85 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 10.26 10.73
Earnings yield (130.22%) (18.81%) (28.84%)
Free cash flow yield (24.39%) (8.73%) (23.03%)

Profitability

Metric EVMN PRLD Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (300.56%) 0.00%
Net margin 0.00% (269.75%) 0.00%
Free cash flow margin 0.00% (148.30%) 0.00%
Return on equity (141.99%) (57.73%) (57.72%)
Return on assets (62.71%) (39.76%) (49.22%)
Return on invested capital (82.46%) 0.00% 0.00%

Growth

Metric EVMN PRLD Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 75.23% 23.21% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric EVMN PRLD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.68 4.07 4.73
Net debt to EBITDA 1.87 1.00 0.96

Dividend

Metric EVMN PRLD Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric EVMN PRLD Biotechnology median
Market cap 309.93m 318.42m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack